Michaela Hoeflich, PA
Medical · Buffalo, NYNPI 1376115162
Payments from drug & device makers
Across 327 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$737
- Lilly USA, LLC$661
- Boehringer Ingelheim$602
- Amgen$555
- Tandem Diabetes Care, Inc.$411
- plus $2K from 24 others
What the payments were for
- Travel & lodging$1,35719%
- Food & beverage$5,55879%
- Education$1092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 20 | $2,051 |
| Novo Nordisk | 66 | $737 |
| Lilly USA, LLC | 60 | $661 |
| Boehringer Ingelheim | 35 | $602 |
| Amgen | 24 | $555 |
| Tandem Diabetes Care, Inc. | 11 | $411 |
| AbbVie | 28 | $409 |
| Insulet Corporation | 18 | $287 |
| Sequel Med Tech, LLC | 5 | $235 |
| Dexcom, Inc. | 11 | $179 |
| Bayer | 5 | $95 |
| IBSA Pharma Inc. | 5 | $92 |
| BETA Bionics, Inc. | 7 | $90 |
| Mannkind Corporation | 4 | $84 |
| Recordati_rare_diseases_inc. | 3 | $65 |
| Amarin Pharma, Inc. | 3 | $56 |
| Radius Health, Inc. | 2 | $52 |
| AstraZeneca | 3 | $49 |
| Amphastar Pharmaceuticals, Inc. | 2 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Ascensia Diabetes Care US Inc. | 2 | $32 |
| BD | 1 | $29 |
| Abbott | 1 | $27 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Almatica Pharma LLC | 1 | $24 |
| Cequr Corporation | 2 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,582
- t:slim X2 Insulin Pump with Control-IQ$236
- TWIIST$137
- Prolia$125
- Ozempic$115
- RYBELSUS$115
- JARDIANCE$110
How this compares
$7,024 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 391 | $514,613 |
| MounjaroTirzepatide | 367 | $478,071 |
| JardianceEmpagliflozin | 257 | $319,470 |
| TrulicityDulaglutide | 152 | $200,330 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $73,603 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $64,478 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $47,173 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $46,916 |
| RybelsusSemaglutide | 36 | $41,269 |
| FarxigaDapagliflozin Propanediol | 38 | $40,898 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $34,734 |
| InvokanaCanagliflozin | 19 | $21,467 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $18,613 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $18,351 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 104 | $17,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $661 | $679,598533 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $737 | $566,937452 claims |
| Boehringer IngelheimJardiance | $602 | $319,470257 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $36 | $49,29047 claims |
| AstraZenecaFarxiga | $49 | $40,89838 claims |
| AbbVieSynthroid | $409 | $16,481158 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $37 | $3,751238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.
Other medical in Buffalo
- Lauren WiatrowskiBuffalo$18K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.